Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
ATAI logo ATAI
Upturn stock ratingUpturn stock rating
ATAI logo

ATAI Life Sciences BV (ATAI)

Upturn stock ratingUpturn stock rating
$1.47
Delayed price
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

04/22/2025: ATAI (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

ratingratingratingratingrating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Analysis of Past Performance

Type Stock
Historic Profit -76.1%
Avg. Invested days 21
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 1.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 04/22/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 305.69M USD
Price to earnings Ratio -
1Y Target Price 8
Price to earnings Ratio -
1Y Target Price 8
Volume (30-day avg) 1703054
Beta 1.25
52 Weeks Range 1.03 - 2.56
Updated Date 04/26/2025
52 Weeks Range 1.03 - 2.56
Updated Date 04/26/2025
Dividends yield (FY) -
Basic EPS (TTM) -0.93

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) 586920%

Management Effectiveness

Return on Assets (TTM) -27.54%
Return on Equity (TTM) -83.16%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 268062395
Price to Sales(TTM) 992.49
Enterprise Value 268062395
Price to Sales(TTM) 992.49
Enterprise Value to Revenue 870.33
Enterprise Value to EBITDA 0.27
Shares Outstanding 199795008
Shares Floating 108999143
Shares Outstanding 199795008
Shares Floating 108999143
Percent Insiders 8.46
Percent Institutions 28.98

Analyst Ratings

Rating 4.67
Target Price 8
Buy 2
Strong Buy 4
Buy 2
Strong Buy 4
Hold -
Sell -
Strong Sell -
Strong Sell -

ai summary icon Upturn AI SWOT

ATAI Life Sciences BV

stock logo

Company Overview

overview logo History and Background

ATAI Life Sciences BV was founded in 2018 as a biopharmaceutical company aiming to transform mental healthcare through innovative therapies. It has grown by acquiring and investing in companies focused on psychedelic and non-psychedelic compounds for mental health disorders.

business area logo Core Business Areas

  • Drug Development: Focuses on discovering, developing, and commercializing therapies for mental health disorders, including depression, anxiety, and addiction.
  • Platform Investments: Invests in and supports various companies with promising mental health treatment approaches, providing funding and resources.

leadership logo Leadership and Structure

The company is led by Florian Brand (CEO) and has a structured organizational model focusing on both internal drug development programs and external investments. Board members include prominent figures in venture capital and biotech.

Top Products and Market Share

overview logo Key Offerings

  • PCN-101 (R-ketamine): A potential treatment for treatment-resistant depression (TRD). Phase 2 data is available. Market share data is not yet applicable due to it still being in trials, however, key competitors include Johnson & Johnson (SPRAVATO) and newer entrants developing novel ketamine analogs.
  • RL-007: A potential treatment for cognitive impairment associated with schizophrenia (CIAS). Phase 2b data is available. Market share data is not applicable due to it still being in trials. Competitors include pharmaceutical companies developing cognitive enhancers for schizophrenia, like Cerevel Therapeutics.

Market Dynamics

industry overview logo Industry Overview

The mental health market is growing rapidly, driven by increasing awareness, prevalence, and unmet needs. There is a surge of interest in psychedelic-assisted therapies and other innovative treatments. Regulations are evolving.

Positioning

ATAI Life Sciences is positioned as a leader in the development of innovative mental health therapies, particularly those involving psychedelic and psychedelic-inspired compounds. They have a diverse portfolio of investments.

Total Addressable Market (TAM)

The global mental health market is estimated to be over $100 billion. ATAI is targeting various segments within this, including depression, anxiety, and schizophrenia. Their positioning allows them to address a large portion of the TAM if their therapies are approved and adopted.

Upturn SWOT Analysis

Strengths

  • Diverse portfolio of drug candidates
  • Strong financial backing
  • Experienced leadership team
  • Focus on innovative therapies

Weaknesses

  • High cash burn rate
  • Regulatory hurdles and uncertainty
  • Dependence on clinical trial outcomes
  • Novelty of psychedelic therapies may limit adoption.

Opportunities

  • Growing market for mental health treatments
  • Potential for breakthrough therapies
  • Partnerships with pharmaceutical companies
  • Expansion into new indications

Threats

  • Competition from established pharmaceutical companies
  • Clinical trial failures
  • Negative perceptions of psychedelic therapies
  • Changes in regulatory landscape

Competitors and Market Share

competitor logo Key Competitors

  • JNJ
  • LYRA
  • GHRS

Competitive Landscape

ATAI differentiates itself through its focus on psychedelic and psychedelic-inspired therapies. JNJ has strong market presence through already approved drug. LYRA is a digital mental health player. All three companies are in the mental health market but take different approaches.

Major Acquisitions

Perception Neuroscience

  • Year: 2020
  • Acquisition Price (USD millions): 20.7
  • Strategic Rationale: Expanded ATAI's pipeline with PCN-101 (R-ketamine) for treatment-resistant depression.

Growth Trajectory and Initiatives

Historical Growth: Since its founding in 2018, growth has been driven by strategic acquisitions and investments in promising mental health therapies. There is no historical revenue to show.

Future Projections: Future growth is dependent on the successful development and commercialization of its drug candidates. Analyst estimates vary widely, but generally anticipate revenue growth in the coming years if products receive regulatory approval.

Recent Initiatives: Recent initiatives include advancing clinical trials for PCN-101 and RL-007, and continuing to evaluate new investment opportunities.

Summary

ATAI Life Sciences is a high-risk, high-reward company focused on innovative mental health therapies, particularly psychedelics. It is positioned in a rapidly growing market but faces significant regulatory and clinical development challenges. While it boasts a diverse portfolio and strong financial backing, it is pre-revenue and reliant on successful clinical trial outcomes. Investors should carefully consider the speculative nature of this stock, given the novelty of the approach.

Similar Companies

GHRSratingrating

GH Research PLC

$9.41
Small-Cap Stock
0%
PASS

GHRSratingrating

GH Research PLC

$9.41
Small-Cap Stock
0%
PASS

JNJratingrating

Johnson & Johnson

$157.75
Large-Cap Stock
0%
PASS

JNJratingrating

Johnson & Johnson

$157.75
Large-Cap Stock
0%
PASS

LYRAratingrating

Lyra Therapeutics Inc

$0.09
Small-Cap Stock
0%
PASS

LYRAratingrating

Lyra Therapeutics Inc

$0.09
Small-Cap Stock
0%
PASS

Sources and Disclaimers

Data Sources:

  • Company filings (SEC)
  • Analyst reports
  • Press releases
  • Company website

Disclaimers:

This analysis is for informational purposes only and does not constitute financial advice. Investment decisions should be based on individual due diligence and consultation with a financial advisor. Market share estimates are approximate and based on available data.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About ATAI Life Sciences BV

Exchange NASDAQ
Headquaters -
IPO Launch date 2021-06-18
Co-Founder & CEO Dr. Srinivas G. Rao M.D., Ph.D.
Sector Healthcare
Industry Biotechnology
Full time employees 54
Full time employees 54

Atai Life Sciences N.V., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of mental health treatments in the United States, Germany, and Canada. The company develops BPL-003, an intranasal formulation of the benzoate salt form of mebufotenin that is in Phase 2a and 2b clinical studies for treatment resistant depression (TRD) and alcohol use disorder; RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator in Phase 2b trial for cognitive impairment associated with schizophrenia; and ELE-101, a serotonergic psychedelic in Phase 2a trial for the treatment of major depressive disorder. It is also developing VLS-01, an oral transmucosal film formulation of N,N-Dimethyltryptamine in Phase 2 clinical study to treat TRD; EMP-01, an oral formulation of R-3,4-methylenedioxy-methamphetamine that is in Phase 2 clinical study for social anxiety disorder; and EGX-A & EGX-B, which are non-hallucinogenic 5-HT2A receptor agonists in preclinical studies for TRD. In addition, the company offers COMP360 for psilocybin therapy; and GRX-917 for the treatment of anxiety, depression, and various neurological disorders. ATAI Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany.

Upturn is now on iOS and Android!

Experience Upturn on your mobile. Install it now!​